Featured Research

from universities, journals, and other organizations

Standard three-drug H. pylori therapy beats newer four-drug regimens in Latin America study

Date:
July 20, 2011
Source:
University of Michigan Health System
Summary:
Clinical trials in Europe and Asia were thought to have pinpointed the best treatment regimen to eradicate the H. pylori bug, an important cause of peptic ulcers and gastric cancer. New results from a large study in Latin America turn those findings on their head, suggesting different populations need different therapies.

Helicobacter pylori, the bacterium known to cause peptic ulcers, is also the primary cause of gastric cancer, which is a leading cancer killer globally.

A large clinical trial at seven sites across Latin America has now found that a standard three-drug regimen for treating H. pylori is more effective, at least in the population studied, than either of two four-drug regimens that proved superior in studies in Europe and Asia.

"This study turns recent literature a bit on its head," says study coauthor William D. Chey, M.D., of the University of Michigan. "Specifically, virtually all other randomized, controlled trials that have tested the four-drug therapy, either sequentially over ten days or concomitantly over five days, have found it superior."

But most of that literature reports on research done in Italy and Taiwan, Chey points out. The new study, published online July 20th by The Lancet, suggests H. pylori eradication approaches need to be validated locally rather than relying on findings from studies of other populations. The authors speculate that geographic variations in H. pylori's resistance to antibiotics might account for part of the discrepancy between populations.

Coordinated by SWOG, one of the National Cancer Institute's cooperative groups, the study took place at both urban and rural sites in Chile, Colombia, Costa Rica, Honduras, Mexico, and Nicaragua.

Researchers randomly assigned 1,463 volunteers infected with H. pylori to one of three treatment regimens, making this the largest trial of its type ever conducted.

One group took a five-day, four-drug regimen, and a second group took these same four drugs but sequentially over a period of ten days. A third group took a standard, 14-day course of two antibiotics plus a proton-pump inhibitor.

Six weeks after starting treatment, each participant was tested for H. pylori infection.

Of those volunteers who took the three-drug, 14-day treatment, 82.2 percent were infection-free. Only 73.6 percent of the group on the five-day regimen and 76.5 percent of those on the ten-day regimen -- the same therapies earlier studies had found superior -- had overcome their infection.

The trial was part of an initiative exploring ways to reduce the incidence of gastric cancer.

"The ultimate goal is to advance the discussion about whether we should approach gastric cancer prevention by mass eradication programs for H. pylori," says lead author E. Robert Greenberg, M.D., an epidemiologist with the SWOG Statistical Center and the Fred Hutchinson Cancer Research Center in Seattle, Wash. "There's lots of thinking that needs to be done and information that needs to be gathered before that decision is made."

Complicating the gastric cancer prevention picture is a small but controversial body of evidence hinting that H. pylori infection may bring benefits as well as harm, reducing rates of childhood asthma and allergies and lowering rates of esophageal cancer, for example.

No large studies comparing the effectiveness of H. pylori treatment regimens have been conducted in the United States, and a pressing question now is which regimen should be recommended to U.S. doctors treating H. pylori. "Before this trial I thought I knew the answer to that question," Chey says. "Now I'm not so sure."

Gastric cancer statistics: According to the International Agency for Research on Cancer, stomach cancer was the fourth most common malignancy and the second leading cause of cancer death in the world in 2008, with an estimated 990,000 new cases and about 738,000 deaths. Approximately 72% of new cases occurred in developing countries.

Funding: Support for the trial came from the Bill & Melinda Gates Foundation (grant OPP43930).

Other authors: G. L. Anderson, Ph.D., and J. J. Crowley, Ph.D., SWOG Statistical Center; G. E. Goodman M.D., Fred Hutchinson Cancer Research Center; D. R. Morgan M.D, M.P.H., University of North Carolina; J. Torres, Ph.D., Instituto Mexicano del Seguro Social, Mexico City, Mexico; L. E. Bravo, M.D., Universidad del Valle, Cali, Colombia; R. L. Domniguez, M.D., Hospital Regional de Occidente, Santa Rosa de Copán, Honduras; C. Ferreccio, M.D., M.P.H., Pontificia Universidad Católica de Chile, Santiago, Chile; R. Herrero, M.D., Ph.D., Fundación INCIENSA, San José, Costa Rica; E. C. Lazcano-Ponce, M.D., Ph.D., and E. Salazar-Martínez, M.D., Dr.Sc., Instituto Nacional de Salud Pública, Cuernavaca, Mexico; M. M. Meza-Montenegro, Ph.D., Instituto Tecnológico de Sonora, Ciudad Obregón, Mexico; R. Peña, M.D., Ph.D., and E. M. Peña, M.D., Centro de Investigación en Demografía y Salud, León, Nicaragua; P. Correa, M.D., Vanderbilt Medical Center; M. Elena Martínez, Ph.D., University of Arizona Cancer Center; M. Valdivieso, M.D., and L. H. Baker, D.O., University of Michigan


Story Source:

The above story is based on materials provided by University of Michigan Health System. Note: Materials may be edited for content and length.


Journal Reference:

  1. E Robert Greenberg et al. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. The Lancet, July 20, 2011 DOI: 10.1016/S0140-6736(11)60825-8

Cite This Page:

University of Michigan Health System. "Standard three-drug H. pylori therapy beats newer four-drug regimens in Latin America study." ScienceDaily. ScienceDaily, 20 July 2011. <www.sciencedaily.com/releases/2011/07/110719194354.htm>.
University of Michigan Health System. (2011, July 20). Standard three-drug H. pylori therapy beats newer four-drug regimens in Latin America study. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2011/07/110719194354.htm
University of Michigan Health System. "Standard three-drug H. pylori therapy beats newer four-drug regimens in Latin America study." ScienceDaily. www.sciencedaily.com/releases/2011/07/110719194354.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) — As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) — Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) — Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Raw: Elephant Undergoes Surgery in Tbilisi Zoo

Raw: Elephant Undergoes Surgery in Tbilisi Zoo

AP (Sep. 18, 2014) — Grand the elephant has successfully undergone surgery to remove a portion of infected tusk at Tbilisi Zoo in Georgia. British veterinary surgeons used an electric drill to extract the infected piece. (Sept. 18) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins